Carotid endarterectomy in patients with significant renal dysfunction  by Sternbergh III, W.Charles et al.
672
Each year, more patients survive chronic renal
insufficiency (CRI) and start dialysis as end-stage
renal disease (ESRD) patients. It is estimated that
these numbers will increase significantly in the next
century.1 Because hypertension and diabetes melli-
tus are so prevalent in this population, these patients
are at significant risk for having concurrent periph-
eral vascular disease.2 As the number of these
patients increases, more will come to vascular sur-
geons for evaluation of their vascular disease.
Patients with ESRD have been widely reported to
have higher perioperative morbidity and mortality
rates and worse long-term outcomes for both car-
diac3,4 and peripheral vascular5,6 operations when
compared with those patients without renal dysfunc-
tion. A recent report stated that carotid endarterec-
tomy (CEA) in patients with ESRD had a prohibitive
operative stroke and death rate, and it questioned the
benefit of CEA in this patient population.7 These
conclusions, however, were based on an experience
with few patients; larger series are needed to provide
a clearer picture of the short- and long-term out-
comes of patients with CRI and ESRD who undergo
CEA. To better understand the perioperative and
long-term outcomes of these patients, we performed
a retrospective chart review of patients who had CRI
or ESRD at the time of their endarterectomy.
METHODS
All patients in whom CRI or ESRD had been
diagnosed were cross-referenced with those who
underwent a CEA at the Alton Ochsner Medical
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Foundation between 1990 and 1997. Patients with
a creatinine level of 1.5 mg/dL or higher at the
time of their CEA were used in the evaluation.
Those patients with acute renal failure were exclud-
ed. These charts were reviewed for patient demo-
graphics, renal function at the time of surgery, peri-
operative morbidity and mortality rates, and long-
term follow-up. Follow-up data were based on
routine postoperative clinic visits and hospital
admissions when they occurred were supplemented
with phone contact with patients whose long-term
data were unavailable from the charts. For the pur-
pose of survival analysis, the study patients were
divided into two groups: those with CRI, defined as
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patients with a creatinine level of 1.5 mg/dL or
higher; and those with ESRD, defined as patients
on long-term hemodialysis or peritoneal dialysis.
Excluding those with CRI or ESRD, all other
patients who underwent CEA in 1993 (116 CEAs
in 105 patients) were used as a control group. This
group was chosen so that complete 4-year survival
data would be available.
Survival data was analyzed by means of the
Kaplan-Meier cumulative survival analysis, with sta-
tistical differences determined by means of the log-
rank test. Baseline demographic data were compared
with chi-square analysis, and perioperative stroke
and death rates were analyzed with the Fisher exact
Fig 1. Creatinine levels of patients with chronic renal insufficiency at the time of carotid endarterectomy.
Table II. Indications for carotid endarterectomy
CRI + ESRD Control
(n = 51) (n = 116) P
CVA 9 (17.6%) 27 (23.3%) NS
TIA 15 (29.4%) 34 (29.3%) NS
Amaurosis 9 (17.6%) 20 (17.2%) NS
Global ischemia 1 (2.0%) 0 (0%) NS
Asymptomatic 17 (33.3%) 34 (29.3%) NS
Redo 6 (11.8%) 8 (6.9%) NS
CRI, chronic renal insufficiency; ESRD, end-stage renal disease;
CVA, cerebrovascular accident; TIA, transient ischemic attack.
Table I. Baseline demographics
CRI + ESRD Control
(n = 44) (n = 105) P
Age 69.5 ± 1.4 68.3 ± 0.8 NS
Female 23 (52.7%) 35 (33.3%) .054
Tobacco use 14 (31.8%) 69 (65.7%) .0001
HTN 42 (95.5%) 70 (66.7%) .0006
DM 18 (40.9%) 32 (30.8%) NS
CAD 25 (56.8%) 61 (58.1%) NS
PVD 26 (59.1%) 44 (41.9%) NS
CRI, chronic renal insufficiency; ESRD, end-stage renal disease;
HTN, hypertension; CAD, coronary artery disease; PVD, periph-
eral vascular disease.
test. Significance was expressed as P being less than
.05. Results were expressed as the mean ± standard
error of the mean.
RESULTS
Demographics. Between 1990 and 1997, 1081
CEAs were performed at our institution, of which
51 were done in 44 patients with CRI or ESRD.
Seventeen patients who had ESRD underwent 19
CEAs, and 27 patients who had CRI underwent 32
CEAs. The mean creatinine level of the patients with
CRI was 2.4 ± 0.2 mg/dL; the creatinine levels of
all patients with CRI are displayed in Fig 1. Table I
lists the demographics of the study and control
groups. In the CRI+ESRD group, there were signif-
icantly more women (P = .054) and a higher preva-
lence of hypertension (P = .0006), when compared
with the control group. Smoking was more common
in the control group (65.7% vs 31.8%; P = .0001).
Age and incidence of coronary artery disease,
peripheral vascular disease, and diabetes mellitus
were similar between the two groups.
Indications for CEA were similar in the two groups
(Table II). Two thirds of patients in both groups had
ipsilateral focal symptoms. Redo endarterectomy com-
prised 11.8% (6 of 51) of patients in the CRI+ESRD
group and 6.9% (8 of 116) in the control group.
Perioperative results. The combined 30-day
perioperative stroke and death rate was 2.0% (0
strokes, 1 death) in the CRI+ESRD group and 2.6%
(3 strokes with one leading to death) in the control
group. In the CRI+ESRD group, the one perioper-
ative death was from myocardial infarction, occur-
ring on postoperative day 29; the patient had been
discharged from the hospital 2 days after her CEA.
In the control group, one death occurred in a
patient with atrial fibrillation who sustained a mas-
sive left hemispheric cerebrovascular accident (CVA)
2 days after a redo right CEA. A second patient, also
in chronic atrial fibrillation, was operated on urgent-
ly for free-floating thrombus at the carotid bifurca-
tion after having an acute CVA; he had a worsening
of his hemiparesis postoperatively. The third stroke
in the control group occurred 10 hours after CEA in
a patient who had sustained an ipsilateral CVA 6
weeks before operation.
Morbidity. In the CRI+ESRD group, perioper-
ative morbidity included three transient cranial
nerve injuries, three episodes of hypertension requir-
ing prolonged hospitalization, one neck hematoma
requiring evacuation, one clotted dialysis access, one
episode of intraoperative cardiac arrest in a patient
who was successfully resuscitated, and one case of
worsening CRI progressing to ESRD. In the control
group, there were two transient cranial nerve
injuries, no neck hematomas requiring exploration,
and one prolonged hospitalization for respiratory
failure in a patient who had a thoracoabdominal aor-
tic aneurysm repair 4 days after his CEA.
Late neurologic events. Table III contains infor-
mation on late neurologic events. At a mean of 26
months, there were three (5.9%) transient ischemic
attacks that had occurred in the CRI+ESRD group
and six (5.2%) in the control group. Late strokes
occurred in two (4.3%) patients in the CRI+ESRD
group and seven (6.0%) patients in the control
group. Strokes occurred on the ipsilateral side of pre-
vious CEA in 50% (1 of 2) of the CRI+ESRD group
and 57% (4 of 7) of the control group. Most late
strokes in the control group (86%) occurred in
patients who were initially symptomatic at the time of
CEA, whereas both late strokes in the CRI+ESRD
group occurred in initially asymptomatic patients.
The follow-up period was at least 1 year or the time
of death in all patients.
Long-term mortality. The long-term mortality
rate was significant (Table IV). The 4-year survival
rate of those patients with ESRD and CRI was 12%
and 54%, respectively, which was significantly less
than the control group survival rate of 72% (P = .04
and P < .0001). In the CRI group, there were five
deaths each in the subgroups, with creatinine levels
ranging from 1.5 to 2.0 mg/dL (n = 14) and high-
er than 2.0 mg/dL (n = 13). Thus, in this small
patient cohort, those with mild CRI had no better
survival rates than those with more severe CRI. In
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Table IV. Long-term survival rates (%)
Patient group 1 yr 2 yr 3 yr 4 yr
Control (n = 105) 94 92 85 72
CRI (n = 27) 88 70 65 54
ESRD (n = 17) 75 53 32 12
CRI, chronic renal insufficiency; ESRD, end-stage renal disease.
Table III. Late stroke
ESRD + CRI Control
Late stroke 2 (4.3%) 7 (6.0%)
Ipsilateral to CEA 1 (50%) 4 (57%)
Symptomatic at CEA 0 (0%) 6 (86%)
CRI, chronic renal insufficiency; ESRD, end-stage renal disease;
CEA, carotid endarterectomy.
1997, the 1-year mortality rate for all ESRD
patients, with an average age of 56 years, at Ochsner
was 19%. The survival cures for all three groups are
depicted in Fig 2.
There were 10 deaths each in the CRI and ESRD
groups. Among the five patients in the CRI group
with creatinine levels of 1.5 to 2.0 mg/dL, none
died of renal failure, whereas two of the five patients
with more severe CRI (creatinine levels higher than
2.0 mg/dL) died of complications of renal failure.
The primary cause of death in the ESRD group was
complications of renal failure (75%), which included
withdrawal of dialysis, severe congestive heart failure
with respiratory complications, and systemic infec-
tion. Cardiac disease (20%) was the second most
common cause of death. None of the patients died
of cerebral vascular disease.
DISCUSSION
There are few reports of CEA in patients with
renal insufficiency in the literature. Rigdon et al7
recently published a series of seven CEAs in six
patients with creatinine levels higher than 2.9
mg/dL, two of whom were on dialysis. The periop-
erative stroke rate was 42% (3 of 7), with two addi-
tional strokes occurring at 3 and 4 months postoper-
atively. Long-term survival was not evaluated. In
Plecha’s review of 9795 CEAs, 216 (2.2%) patients
had chronic renal failure. Both perioperative stroke
and death were reported to be “significantly higher”
in these patients than the 2.0% and 1.5%, respective-
ly, in the entire patient cohort. Neither the magni-
tude of the increased perioperative morbidity/mor-
tality nor long-term outcome were discussed.8
Our perioperative outcome was markedly differ-
ent than these series, with a combined stroke/mor-
tality rate of 2.0% in patients with CRI or ESRD.
This event rate was not significantly different from
the 2.6% stroke/death rate in the control group.
Thus, the presence of significant renal disease did not
appear to adversely affect early outcome. Incidence of
late stroke in this patient group (4.3%) was not sig-
nificantly different from our control group (6.0%).
These data are in contrast to those of Rigdon et al,
who noted a late stroke rate of 28.6% (2 of 7) in
patients with CRI or ESRD. The morbidity was
higher in our CRI+ESRD group when compared
with the control group, but was not prohibitive.
The alarming finding in our study was the remark-
ably high long-term mortality rate of this patient
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Fig 2. Kaplan-Meier survival curve of patients with chronic renal insufficiency (CRI), patients with end-
stage renal disease (ESRD), and control patients. Survival is significantly worse in those patients with
CRI and ESRD when compared with the control group, with P = .04 and P < .0001, respectively.
cohort, especially those with ESRD. The 5-year sur-
vival rate for all ESRD patients is estimated at 40% for
patients in the United States, a figure which drops to
15% in age-matched ESRD patients with diabetes
mellitus.9 This latter group is similar to our study
group and, indeed, has a similar mortality rate. Our
yearly mortality rate of 19% for all ESRD patients at
our facility likely reflects the advanced age and signif-
icant comorbidities of this patient population.
In patients who do not have ESRD, the severity
of CRI did not appear to correlate with death.
Patients with mild CRI (creatinine levels of 1.5 to
2.0 mg/dL) had the same 4-year mortality rate as
those with more severe CRI (creatinine levels high-
er than 2.0 mg/dL). Interestingly, none of the
patients with mild CRI died of renal failure.
Intuitively, one would expect that those with severe
CRI would fare worse than those with mild CRI,
but this hypothesis was not supported by the data.
However, because of the small sample size of these
subgroups, a type II error was certainly possible; no
firm conclusions can be drawn.
Baseline demographics of the control group and
the study group were fairly well matched. There
were more women in the CRI+ESRD group, which
would potentially bias the results against this group;
women may have a higher perioperative stroke rate
than men after CEA.10,11 However, stroke rates
were similar between the two groups. As expected,
the nearly ubiquitous presence of hypertension in
the CRI+ESRD group was higher than in the con-
trol group, but this variable has not been a predictor
of perioperative outcome in CEA.10 The control
group (all patients undergoing CEA in 1993) was
chosen so that complete survival data would be
available, because this was a primary endpoint in this
study. Indeed, the long-term survival rate in our
control group was very similar to that reported in
large randomized trials of carotid disease,11,12 sug-
gesting that it is indeed a representative control.
Although the use of the entire cohort of CEA
patients from 1990 to 1997, or a subgroup picked
by a case control method, may have produced a
more statistically “appropriate” control group, it is
highly unlikely that the conclusions of this study
would be altered with their use.
Does the high long-term mortality rate of these
patients diminish or negate the effectiveness of 
CEA in preventing future stroke? In the North
American Symptomatic Carotid Endarterectomy
Trial (NASCET), the Kaplan-Meier curves for stroke
diverged between the medically and surgically treat-
ed groups at approximately 3 months of follow-up,
with clear benefit to the surgical group by 6 to 12
months.12 At 2 years, the ipsilateral stroke rate was
26% in the medically treated patients and 9% in the
surgically treated patients. In the Asymptomatic
Carotid Artery Study (ACAS), a randomized trial of
asymptomatic carotid disease, the Kaplan-Meier
curves for stroke between surgically and medically
treated groups did not begin to diverge until 18 to
24 months, and only at 5 years did the differences
become statistically significant (5.1% vs 11% for
surgery vs medical treatment, respectively).11 Most
patients with significant carotid disease and ESRD
have died at 5 years of follow-up.13
Based on these data, it would appear that ESRD
patients with symptomatic disease may still benefit
from CEA, but those with asymptomatic disease
may not live long enough to enjoy a significant
reduction in stroke risk.
These speculations must be tempered, however,
by the knowledge that the natural history of signifi-
cant carotid disease in this patient cohort is largely
unknown. These patients would not have been eligi-
ble for the NASCET and ACAS trials because of
their renal disease. It may be possible that the risk of
stroke in patients with ESRD is greater than that of
the medically treated groups in these studies.
Significant repetitive hypotension occurring during
dialysis may predispose patients to hypoperfusion-
induced stroke, for instance. However, most strokes
caused by carotid bifurcation disease are embolic in
nature and not hemodynamic.
The prevalence of ESRD is continuously increas-
ing. In 1990, there were 180 cases of ESRD per
1,000,000 members of the US population, a rate
which has increased by 7.5% each year. By the year
2001, there are expected to be 300,000 patients
with ESRD, with 75,000 new patients in that year
alone.1 Patients with renal insufficiency have a
greater propensity to develop carotid occlusive dis-
ease than age-matched controls.13 Vascular surgeons
can expect to see a larger number of patients with
ESRD coming to them for evaluation of their
carotid occlusive disease.
CONCLUSION
The high long-term mortality rate of the patients
in our study suggests that the criteria for operative
treatment that are applied to the routine patient
population may not be applicable to those with CRI
or ESRD. Although the operation can be performed
safely in patients with CRI or ESRD, prophylactic
CEA in the asymptomatic patient with renal dys-
function, especially one with ESRD, may have little
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effect in improving the long-term stroke-free sur-
vival of these patients. Although operative treatment
decisions should be individualized to each patient,
based on our data, we would not recommend CEA
in asymptomatic patients with ESRD.
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